Project Grant R56CA286906
Award Date
9/12/24
Completion Date
8/31/25
Dollars Obligated
$165K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
The National Cancer Institute awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Northwestern University to advance the science of brain metastases from breast cancer. The $895,779 grant, awarded on August 1, 2024, will fund a multi-year effort to: 1) understand the fundamental biology of HER2+ breast cancer metastases to the brain through patient tissue-based genetic analysis, 2) develop real-time visualization of cancer cells and neural stem cells targeting...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $557,418 to The Trustees of Columbia University in the City of New York to conduct research aimed at targeting the SMARCA2 protein as a therapeutic approach for lung cancers with SMARCA4 deficiencies. The key research objectives are to: Assess the effects of SMARCA2 degradation on the progression of SMARCA4-deficient lung cancer using genetically engineered mouse models....
The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant, titled "Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach," aims to leverage the university's recently developed method to generate pulmonary neuroendocrine cells from human pluripotent stem cells. These cells can be transformed to closely...
This $160,642 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at New York University School of Medicine to investigate the role of amyloid beta in the brain tumor microenvironment. The project aims to characterize how amyloid beta facilitates immunosuppression and inhibits macrophage-mediated cancer cell phagocytosis in brain metastases. The researchers will determine if targeting amyloid beta, alone or in combination with...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $124,548 to the University of California, Los Angeles (UCLA) to investigate the cellular and molecular mechanisms that allow glioblastoma, an aggressive brain cancer, to adapt and resist targeted therapies. The research aims to elucidate how the unique brain microenvironment drives lineage transformations in glioblastoma cells, enabling them to rapidly develop resistance to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Sloan-Kettering Institute For Cancer Research aims to investigate the relationship between leptomeningeal cancer cell growth and leptomeningeal-generated CXCL1 signaling. The $730,398 award, with a period of performance from March 2025 to February 2030, will leverage mouse models and clinical samples to mechanistically dissect the CXCL1-CXCR2 signaling axis within the leptomeningeal...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at understanding the molecular mechanisms underlying the adeno-to-squamous transition observed in non-small cell lung cancer patients treated with KRAS inhibitors. The key objectives are to: Identify chromatin regulators that drive the adeno-to-squamous transition through a perturbation screen, and then...
This federal Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,400.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding the metabolic mechanisms that drive the emergence and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The researchers will use mouse models and patient-derived xenograft models to manipulate components of the...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, is focused on uncovering the core mechanisms driving lineage plasticity in EGFR-mutant lung adenocarcinoma (LUAD). The $631,156 award will fund a 5-year research project conducted by the Icahn School of Medicine at Mount Sinai to systematically investigate the genetic, transcriptomic, and epigenomic changes underlying the transformation of LUAD to the more...